Adamis Pharmaceuticals Corp (NASDAQ:ADMP) – Equities researchers at Dawson James reduced their Q3 2020 EPS estimates for Adamis Pharmaceuticals in a research report issued on Tuesday, August 13th. Dawson James analyst J. Kolbert now forecasts that the specialty pharmaceutical company will post earnings of $0.04 per share for the quarter, down from their prior forecast of $0.10. Dawson James has a “Buy” rating on the stock. Dawson James also issued estimates for Adamis Pharmaceuticals’ Q1 2021 earnings at $0.02 EPS and Q2 2021 earnings at $0.02 EPS.
Several other research analysts have also recently issued reports on ADMP. B. Riley raised shares of Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a report on Tuesday, July 23rd. ValuEngine raised shares of Adamis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, August 10th. Maxim Group set a $6.00 target price on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 9th. Raymond James set a $4.00 target price on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 10th. Finally, Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $3.87.
Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). The firm had revenue of $5.77 million for the quarter, compared to analysts’ expectations of $5.82 million. Adamis Pharmaceuticals had a negative return on equity of 79.65% and a negative net margin of 205.32%.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Leisure Capital Management grew its position in Adamis Pharmaceuticals by 4.5% during the first quarter. Leisure Capital Management now owns 115,724 shares of the specialty pharmaceutical company’s stock worth $244,000 after buying an additional 4,967 shares during the period. National Asset Management Inc. boosted its position in Adamis Pharmaceuticals by 28.9% during the first quarter. National Asset Management Inc. now owns 29,920 shares of the specialty pharmaceutical company’s stock worth $64,000 after acquiring an additional 6,710 shares during the last quarter. Jane Street Group LLC acquired a new stake in Adamis Pharmaceuticals during the fourth quarter worth approximately $31,000. BlackRock Inc. boosted its position in Adamis Pharmaceuticals by 1.5% during the second quarter. BlackRock Inc. now owns 962,687 shares of the specialty pharmaceutical company’s stock worth $1,252,000 after acquiring an additional 14,312 shares during the last quarter. Finally, Raymond James & Associates boosted its position in Adamis Pharmaceuticals by 56.5% during the fourth quarter. Raymond James & Associates now owns 49,596 shares of the specialty pharmaceutical company’s stock worth $112,000 after acquiring an additional 17,900 shares during the last quarter. Institutional investors own 19.49% of the company’s stock.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Read More: Economic Reports
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.